Alzheimer’s Experts: Lecanemab Is A Win, But Also Just The Beginning

The path to a disease-modifying treatment for Alzheimer’s disease is paved with failure after disappointing failure, so when the Phase III Clarity AD clinical trial of Eisai Co., Ltd./Biogen, Inc.’s lecanemab was presented on day one of the Clinical Trials on Alzheimer’s Disease (CTAD) meeting in San Francisco the data set a positive tone for the rest of the conference. Nevertheless, as AD experts noted during a panel on 1 December, the final day of CTAD, many challenges remain.

Eisai presented detailed results from Clarity AD on 29 November that showed lecanemab, an amyloid protofibril-targeting antibody, provided a 27% slowing of disease progression on the primary endpoint of Clinical Dementia Rating-Sum of Boxes (CDR-SB). (Also see "Eisai/Biogen’s Lecanemab Effective Across Endpoints, But Will Safety Limit Use?" - Scrip, 30 November, 2022